Elda Hegmann obtained an M.Sc. in Mexico from Universidad Autónoma de Coahuila and CIQA and her Ph.D. at Université Laval in Québec (Canada). After postdoctoral research positions at Queen’s University, University of Manitoba, and the National Research Council Canada (NRC), and as a research officer at the NRC, she moved to the USA to join AMLCI (formerly known as LCI) at Kent State University in 2011 and BSCI in 2017. Dr. Hegmann’s research in biomaterials has produced several peer-reviewed articles and 4 patents. Dr. Hegmann serves as the CEO of two start-up companies, TOREL LLC and Biostica LLC. She is a member of the Advanced Materials and Liquid Crystal Institute (AMLCI)/Materials Science Graduate Program (MSGP), the Biomedical Sciences (BMS) program, and the Brain Health Research Institute (BHRI). Her research is divided into three main directions. The first direction focuses on tissue regeneration, such as to shorten wound healing times. The second direction aims at the development of microneedles/micropillars as biodegradable and effective transdermal drug delivery systems, as well as vesicles/liposomes (based on lyotropic liquid crystal systems) as a means for early detection of diseases and for drug delivery systems. The third direction aims at using LCs and polymer membranes that are used in the development of devices for toxic gases and vapor sensors.